Search

Your search keyword '"Osman, Rasha Alsamani"' showing total 6 results
Start Over Author "Osman, Rasha Alsamani"
6 results on '"Osman, Rasha Alsamani"'

2. EMT-Related Markers in Serum Exosomes are Potential Diagnostic Biomarkers for Invasive Pituitary Adenomas

Author

Chen, Kelin, Li, Guoge, Kang, Xixiong, Liu, Pinan, Qian, Lingye, Shi, Yijun, Osman, Rasha Alsamani, Yang, Zhijun, and Zhang, Guojun

Subjects
Neuropsychiatric Disease and Treatment, invasiveness, epithelial-mesenchymal transition, pituitary adenoma, serum exosomes, TGF-β/Smad, Original Research
Abstract

Purpose Assessing the invasiveness of pituitary adenomas (PAs) is critical to making the best surgical and treatment plan. However, it is difficult to determine the invasiveness of pituitary adenomas based on current clinical methods, such as imaging and histological methods. The present article aims to investigate noninvasive methods to discover viable biomarkers for invasive pituitary adenomas and provide a basis for early intervention of pituitary adenomas. Methods E-cadherin, N-cadherin, Epcam, TGF-β, Smad3, and Smad7 were detected in the tissues and exosomes in 10 cases of invasive PAs and 10 cases of noninvasive PAs by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemical analysis. Results Compared with that in the noninvasive group, the expression of N-cad in the exosomes of the invasive group was significantly increased, and the expression of E-cad and Epcam was reduced. In the invasive group, the expression levels of TGF-β1 and Smad3 were reduced. These results were consistent across exosomes and groups. In further cell experiments, the EMT ratio in the SIS3 treatment group, and especially in the TGF-β1 plus SIS3 treatment group (P, Graphical Abstract

Published
2021

5. EMT-Related Markers in Serum Exosomes are Potential Diagnostic Biomarkers for Invasive Pituitary Adenomas

Author

Chen,Kelin, Li,Guoge, Kang,Xixiong, Liu,Pinan, Qian,Lingye, Shi,Yijun, Osman,Rasha Alsamani, Yang,Zhijun, Zhang,Guojun, Chen,Kelin, Li,Guoge, Kang,Xixiong, Liu,Pinan, Qian,Lingye, Shi,Yijun, Osman,Rasha Alsamani, Yang,Zhijun, and Zhang,Guojun

Abstract

Kelin Chen,1– 3,* Guoge Li,1,* Xixiong Kang,1– 3 Pinan Liu,4 Lingye Qian,1 Yijun Shi,1 Rasha Alsamani Osman,1 Zhijun Yang,4 Guojun Zhang1– 3 1Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2NMPA Key Laboratory for Quality Control of In Vitro Diagnostics, Beijing, China; 3Beijing Engineering Research Center of Immunological Reagents Clinical Research, Beijing, People’s Republic of China; 4Department of Neurosurgery of Beijing Tiantan Hospital, Capital Medical University, Beijing, China*These authors contributed equally to this workCorrespondence: Guojun ZhangDepartment of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, No. 119 Nansihuan West Road, Fengtai District, Beijing, China, Email guojun.zhang@ccmu.edu.cnZhijun YangDepartment of Neurosurgery of Beijing Tiantan Hospital, Capital Medical University, NO. 119 Nansihuan West Road, Fengtai District Beijing, China Email zhijunyang@ccmu.edu.cnPurpose: Assessing the invasiveness of pituitary adenomas (PAs) is critical to making the best surgical and treatment plan. However, it is difficult to determine the invasiveness of pituitary adenomas based on current clinical methods, such as imaging and histological methods. The present article aims to investigate noninvasive methods to discover viable biomarkers for invasive pituitary adenomas and provide a basis for early intervention of pituitary adenomas.Methods: E-cadherin, N-cadherin, Epcam, TGF-β, Smad3, and Smad7 were detected in the tissues and exosomes in 10 cases of invasive PAs and 10 cases of noninvasive PAs by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemical analysis.Results: Compared with that in the noninvasive group, the expression of N-cad in the exosomes of the invasive group was significantly increased, and the expression

Published
2021

6. Potential biomarkers identified by tandem mass tags based quantitative proteomics for diagnosis and classification of Guillain–Barré syndrome.

Author

Ding, Yaowei, Shi, Yijun, Wang, Lijuan, Li, Guoge, Osman, Rasha Alsamani, Sun, Jialu, Qian, Lingye, Zheng, Guanghui, and Zhang, Guojun

Subjects
GUILLAIN-Barre syndrome, PERIPHERAL neuropathy, PROTEOMICS, ENZYME-linked immunosorbent assay, BIOMARKERS
Abstract

Background and purpose: Guillain–Barré syndrome (GBS) is an acute inflammatory autoimmune and demyelinating disease of the peripheral nervous system. Currently, valid biomarkers are unavailable for the diagnosis of GBS. Methods: A comparative proteomics analysis was performed on the cerebrospinal fluid (CSF) from 10 patients with GBS and 10 patients with noninflammatory neurological disease (NND) using the tandem mass tags technique. The differentially expressed proteins were analyzed by bioinformatics, and then the candidate proteins were validated by the enzyme‐linked immunosorbent assay method in another cohort containing 160 samples (paired CSF and plasma of 40 patients with GBS, CSF of 40 NND patients and plasma of 40 healthy individuals). Results: In all, 298 proteins were successfully identified in the CSF samples, of which 97 differentially expressed proteins were identified in the GBS and NND groups. Three key molecules were identified as candidate molecules for further validation. The CSF levels of TGOLN2 and NCAM1 decreased in GBS patients compared with NND patients, whereas the CSF levels of APOC3 increased. The enzyme‐linked immunosorbent assay results were consistent with our proteomics analysis. Interestingly, in the validation cohort, serum APOC3 levels in the GBS group were consistent with those in the CSF samples and significantly higher than those in the healthy control group. Conclusions: Our preliminary data suggest that the CSF protein expression profile of patients with GBS is different from that of patients with NND. Moreover, alterations of TGOLN2, NCAM1and APOC3 may be used as novel biomarkers for identifying patients with GBS. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results